ClinicalTrials.gov
public full text
Public Domain
Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
At the completion of primary follow-up of various Medeor Transplant studies (called parent studies), subjects receiving Medeor's cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years), in order to evaluate for long-term safety.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product#1173166
- TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients#1072407
- Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.#992462
- Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract#1058919
- Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda#1085285
Record · ID 1031760
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive